
Original Article

Inflammation and its Correlation with Cardiovascular Risk Factors in Patients with Chronic Kidney Disease

Gjergji Zheni¹, Gjata Margarita², Bulo Anyla³, Tase Mihal², Koroshi Alketa⁴, Barbullushi Myftar⁴

¹Hospital Center "Dr. Xh. Kongoli" Department of Nefrology and Hemodialysis, Elbasan, ²University Hospital Center "Mother Teresa", Service of Internal Medicine and Hypertension, Tirana, ³University Hospital Center "Mother Teresa", Biochemical Service, Tirana, ⁴University Hospital Center "Mother Teresa", Service of Nephrology, Tirana, Albania

Abstract

Background. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Markers of inflammation are also elevated in chronic renal patients. High levels of C-reactive protein (CRP) are a strong prognostic factor for cardiovascular morbidity and mortality both in non uremic and uremic patients. Increased CRP predicts cardiovascular mortality in hemodialysis patients (pts.). The aim of our study was to assess the relationship between the prevalence of CRP and the prevalence of cardiovascular disease in pre-dialysis and hemodialysis patients.

Methods. 55 patients with CKD were enrolled in this study. 30 pts were in CKD not requiring dialysis (pre-dialysis) and were hospitalized at the Department of Internal Medicine in the University Hospital Center "Mother Teresa" in Tirana, Albania, during the period of September 2005 to May 2006, while 25 pts were dialyzed in Hospital Center of "Dr. Xh. Kongoli" Elbasan, Albania. The patients were divided in two groups based on the levels of CRP. The first group comprised patients that presented CRP levels lower than 6 mg/l and the second group comprised those presenting CRP levels higher than 6mg/l. For both groups we evaluated cardiovascular risk factors such as: systolic and diastolic blood pressure, albumin level, total cholesterol, anemia and dose of EPO treatment.

Results: 50% of pre-dialysis and 52% of dialysis pts presented with elevated concentration of CRP > 10mg/l. In the first or pre-dialysis group, two patients (7%) presented with Ischemic Heart Disease, one patient (3%) had a history of myocardial infarction and 3 patients (10%) had congestive cardiac failure (CCF). In the dialysis group two patients (8%) presented ischemic heart disease and 5 patients (20%) with CCF. All patients with cardiovascular disease presented with elevated concentration of CRP. Considering all patients enrolled, a significant correlation ($p < 0.003$), between elevated levels of CRP and cardiac morbidity has been found, but considering each group, pre-dialysis and dialysis, the

correlation was not significant, most probably because of the limited number of patients enrolled.

Conclusion. Regardless of the stage, CKD patients (pre-dialysis and dialysis) with elevated levels of CRP (as a single CVD marker) were associated with higher cardiovascular morbidity.

Keywords: inflammation, C-Reactive Protein, cardiovascular risk.

Introduction

Patients with chronic kidney disease (CKD) have a higher mortality rate when compared to the general population [1]. The risk of cardiovascular events is 100 times higher in end-stage renal disease (ESRD) patient when compared with age and sex matched controls. This burden of cardiovascular disease in CKD reflects the additive effect of the presence of traditional (such as hypertension, diabetes mellitus, obesity, hiperlipidemia and smoking) and non-traditional risk factors (C-reactive protein (CRP)) for cardiovascular events [2]. Cardiovascular risk in patients with CKD has gained crucial interest in the current clinical research. In addition, the cardiovascular risk in renal insufficiency is perceived as an important public health problem, and preventing and curing cardiovascular complications in patients with renal dysfunction is considered a true priority [3,4]. Cardiovascular complications are the leading cause of death in patients with end-stage renal disease (ESRD), accounting for 40% of deaths in these patients [5,6]. Markers of inflammation are also elevated in CKD patients [7-9]. Inflammation in CKD is a multifactor process, and it seems likely that this process, at least in part, mediates the effect of most traditional and nontraditional risk factors [10-12]. High levels of CRP are a strong prognostic factor for cardiovascular morbidity and mortality both in non uremic and uremic patients [8,13]. An elevated serum C-reactive protein has been shown to be strongly predictive of cardiac morbidity and mortality in dialysis patients [14,15]. However the significance of the higher levels in the pre-dialysis period has not been studied extensively. Several authors have found that

overall cardiovascular morbidity and mortality were significantly higher in hemodialysis patients with elevated CRP levels [7,15-17].

Single measurements of CRP predict cardiovascular morbidity in patients with chronic renal disease. Therefore we investigated the effect of high concentrations of CRP on cardiovascular morbidity in patients with chronic renal disease.

The aim of our study was to assess the relationship between the prevalence of CRP and prevalence of cardiovascular disease in pre-dialysis and hemodialysis patients.

Patients and methods

We enrolled 55 patients, out of whom 30 patients were hospitalized as pre-dialysis and 25 were stable hemodialysis patients (mean age in pre dialysis 58 ± 15 and in dialysis 45 ± 12 years). Both pre-dialysis and dialysis patients were divided in groups according to the level of CRP (<6 mg/l). CRP was assessed using a high standard sensitivity test. At baseline, a complete clinical history was obtained and a physical examination performed. The presence of CVD was also examined by asking them for a former history of CVD, by physical examination and ECG.

Ischemic heart disease (IHD) has been determined by the presence of chest pain, precipitated by exertion or stress and relieved by rest or nitrates, ECG evidences of myocardial ischemia, history or presence of myocardial infarction and coronary artery bypass. Hypertension was considered to be present when the sitting blood pressure (BP) was $\geq 140/90$ mm/Hg or when regardless of BP values, the patient was under antihypertensive therapy. Blood pressure was measured with the use of validated mercury sphygmomanometers. 25 patients were treated with HD three times a week for 4 hours. The levels of Salb have been measured and hypoalbuminemia was defined as Salb <4 gr/dl. GFR was calculated using the Cockcroft-Gault formula. BMI was calculated and expressed as kg/m². We evaluated the anemia for each patient according to the level of haemoglobin

(Hb <13 mg/dl in men and <12 mg/dl in women) and hematokrit $<33\%$.

Statistical analysis

The study was cross-sectional. Statistical analysis was performed using SPSS version 7.5. The initial estimated GFR and the biological, laboratory and inflammatory parameters expected to influence mortality were used as independent variables. Differences in parameters of interest between groups were sought by the Pearson's correlation. For comparison of qualitative variables we used Fisher's exact test and Student's test for quantitative variables. Data are expressed as mean \pm SD. Statistical significance was assumed if $P < 0.05$.

Results

Pre-dialysis group consisted of 16 men and 14 women (mean age 58 ± 15 years), while 14 men and 11 women were evaluated in the second group (HD patients) with mean age of 45 ± 12 years.

Primary renal diseases in the pre-dialysis group were presented in Figure 1.




Fig. 1. Primary renal disease in the pre-dialysis group

In the first group 20% of patients were with Diabetes mellitus (DM), 23% with renovascular hypertension (RVH), 7% with chronic glomerulonephritis (GN), and 50% with chronic interstitial pyelonephritis (IPN).

Table 1. Clinical and biochemical characteristics of the pre-dialysis group

	Group I (PCR >6 mg/l) n = 18	Group II (PCR ≤ 6 mg/l) n = 12	P value
CRP (mg/l)	17.9 (8-93.3)	4.015 (1-6)	0.001
Albuminemia (g/l)	50.14 \pm 6.46	57.36 \pm 5.21	0.017
Cholesterol (mg/dl)	179.9 \pm 47.33	194.96 \pm 60.28	NS
Hb (g/dl)	8.79 \pm 1.41	9.27 \pm 1.32	0.05
EPO-s (IU/kg/week)	5444 \pm 1149	5000 \pm 1044.47	0.03
Hb/EPO	0.0018 \pm 0.001	0.0020 \pm 0.00065	0.004

Data of prevalence of albuminemia levels, nutrition, anemia, and response to EPO therapy in the pre-dialysis group (Table 1).

The comparison of blood pressure, proteinuria, and CCR between the two groups in pre-dialysis patients is presented in Table 2.

Prevalence of C- reactive protein among patients in pre-dialysis group is presented in Figure 2. 58% presented CRP levels > 6 mg/l and only in 38% of them CPR levels were lower than 3mg/l.

Table 2. Blood pressure, proteinuria, and CCr of the pre-dialysis group

	Group I (PCR>6 mg/l) n =18	Group II (PCR≤6 mg/l) n =12	Value of P
Systolic pressure (mm Hg)	166.67±17.49	177±17.12	NS
Diastolic pressure (mmHg)	98.06±9.42	104±8.74	0.04
Proteinuria	1.54 ±2.04	1.2 ± 1.54	NS
Δ CCr (ml/min/1.73 m ²)	15.68±10.5	19.03±13.35	NS




Fig. 2. Prevalence of CRP among patients in pre-dialysis stage




Fig. 3 CVD (Cardio Vascular Disease) in predialytic group

In the first or pre-dialysis group: two patients (7%) presented **IHD** (Ischemic Heart Disease, one patient (3%) a history of **IM** (myocardial infarction), 3 patients (10%) **CHD** (congestive heard disease) and one patient, (3%) presented **AP** (Angina Pectoris), Figure 3.




Fig. 4. Primary renal disease in hemodilysis group

In the second group of patients 4% were with polycystic kidney disease (Ren Polycistic), 4% with diabetic

mellitus type 2 (DM), 4% with chronic glomerulonephritis (GN), and 88 % with chronic pyelonephritis PN, Figure 4.



Clinical and biochemical characteristics of the study subjects for the second group (hemodialysis) (Table 4). Prevalence of C- reactive protein among patients in hemodialysis is show in Figure 5.

60% presented CRP levels > 6 mg/l and only in 40% of them CPR levels were lower than 3mg/l.

In the dialysis group: two patients (8%) presented **IHD** (Ischemic Heart Disease), five patients (20%) **CCF** (congestive cardiac failure) and one patient (4%) **AP** (Angina Pectoris), Figure 6. All the patients with cardiovascular disease presented elevated concentration of CRP. Considering all patients enrolled, a significant correlation ($p < 0.003$), between elevated levels of CPR and cardiac morbidity has been found, but considering each group, pre-dialysis and dialysis, the correlations were not significant, because the limited number of patients enrolled.

Table 4. Clinical and biochemical characteristics of the study subjects in hemodialysis patients

	Group I (PCR>6 mg/l) n = 18	Group II (PCR≤6 mg/l) n = 12	P-value
CRP (mg /l)	13.8(10-29.5)	1.65 (0.5-3.9)	0.001
Albuminemia (g/l)	3.63±0.48	4±0.33	0.025
Cholesterol (mg/dl)	175.23±30.88	175.75±29.67	NS
Hb (g/dl)	8.15±1.43	8.73±1.9	0.05
EPO-s (IU/kg/week)	4769.23±2241.8	5500±1732.05	0.03
EPO/Hb	632.68±333.98	664.14±260.34	0.004

**Fig. 5.** Prevalence of inflammation in hemodialysis patients**Fig. 6.** CVD (Cardio Vascular Disease) in Hemodialysis patients

Discussion

CVD is the main cause of mortality and morbidity among patients with CRF. CVD accounts for 40% of deaths, 10-30 folds higher than in the healthy population. Uremia itself is considered to be an inflammatory status [18].

Our data suggest that prevalence of inflammation is high for the two groups of patients; 50 % of the pre-dialysis patients presented higher levels of CRP and 52% of dialyzed patients present higher levels of CRP >10 mg/l. This is due to the fact that the mean age of the patients in the two groups was relatively young. Our hemodialysis center is a very new center, so the study includes a limited number of patients.

According to our data 23% of pre-dialysis patients have signs of CVD; 7% have IHD, 3% have myocardial infarction IAM, 10% have CCF (congestive cardiac failure), and 3% have AP.

Also 32% of dialyzed patients have signs of CVD, 20% of them have chronic heart failure (CCF), 8% have IHD

and 4% AP. All of them present higher level of C-reactive protein CRP > 6mg/ l.

Patients who have higher levels of CRP presented lower hemoglobin levels. These patients, who used to take higher dose of EPO, did not respond sufficiently to this therapy.

Also CRP did not correlate with creatinine clearance level. We found that the EPO resistance correlated with low levels of albumin and BMI in hemodialysed patients (68 %) $p < 0.025$.

Our patients in pre-dialysis stage who have higher levels of CRP, did not present lower levels of albumin. Levels of CRP indirectly correlated with levels of albumin ($r = -0.5$, $P < 0.025$).

Our dialyzed patients who have higher levels of CRP present lower albumin levels and levels of CRP indirectly correlate with albumin levels ($r = -0.25$, $P < 0.03$). Albumin levels and CRP levels (high in patients with CVD) probably reflect the presence of the Malnutrition, Inflammation in dialyzed patients.

Conclusions

Our study shows a high coefficient of inflammation in patients with CVD.

High prevalence of CRP is shown at the pre-dialysis stage, so that the monitoring and its correction at this stage would be one of the efficient methods to reduce cardiovascular morbidity and mortality. Patients with elevated levels of CRP manifested lower value of Hb and they resisted to the EPO treatment (i.e. its normalization should be considered before start with EPO therapy, aiming at its cost reduction).

CRP correlated in our study with non traditional risk factor like albuminemia, anemia which interrelated with

each-other potentially increasing the risk of CVD. Finally, regardless of the stage, CKD patients (pre-dialysis and dialysis) with elevated levels of CRP (as a single CVD marker) were associated with higher cardiovascular morbidity.

Conflict of interest statement. None declared.

References

1. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol* 2006; 17(7): 2034-47.
2. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman Breen C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. *JAMA* 2005; 293(14): 1737-45.
3. Kaysen GA. The microinflammatory state in Uremia: Causes and Potential Consequences. *J Am Soc Nephrol* 2001; 12: 1549-1557.
4. Carmine Zoccali, Francesca Mallamaci and Giovanni Tripepi Novel cardiovascular risk factors in End-stage Renal Disease. *J Am Soc Nephrol* 2004; 15: S 77-S80.
5. Gérard M. London, Sylvain J. Marchais, Alain P. Guerin, Fabien Metivier, Hassan Adda, and Bruno Pannier. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. *Kidn Int* 2003; Vol 63, Suppl. 84: S88 – S93.
6. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? *Nephrol Dial Transplant* 2000; 15: 454 - 457.
7. Brenner RM; Wrona EM. The epidemic of cardiovascular disease in end - stage renal disease. *Curr Opin Nephrol Hypertens* 1999; 8: 927 - 932.
8. Levin A, Stevens L, McCullough PA: Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease. *Postgrad Med* 2002; 111: 53-60.
9. Ross R: Atherosclerosis. An inflammatory disease. *N Engl J Med* 1999; 340: 115-126.
10. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? *Kidney Int* 2002; 62: 1791-1798.
11. Zoccali C: Inflammation and atherosclerosis in end-stage renal disease. *Blood Purif* 2003; 21: 29-36.
12. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S: Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. *J Am Soc Nephrol* 1997; 8: 1764-1770.
13. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K: Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. *J Am Coll Cardiol* 2001; 37: 412-417.
14. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. *Hypertension* 2002; 40: 41-46.
15. Foley RN; Parfrey MB; Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *AJKD* 1996; Vol. 32, Nr. 5, Suppl 3, f. 112 - 119.
16. Resuli M; Idrizi A; Tase M; Barbullushi M. Cardiovascular risks in non dialysed patients with chronic renal failure. *BANTAO 5th Congress. Proceedings* 2001; pp 88 - 90.
17. Stenvinkel P; Heimbürger O; Lindholm B; Kaysen GA; Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationship between malnutrition, inflammation and atherosclerosis. (MIA syndrome). *Nephrol Dial Transplant* 2000; 15: 953 – 960.
18. European Best Practice Guidelines for Haemodialysis *NDT* 2002; Vol 17.